Literature DB >> 19004604

Nedd4L expression is downregulated in prostate cancer compared to benign prostatic hyperplasia.

X Y Hu1, Y M Xu, Q Fu, J J Yu, J Huang.   

Abstract

AIMS: To characterize aspects of Nedd4L in prostate cancer (PC) by assessing its expression in hyperplastic and malignant prostate tissue, and to correlate findings with PC histologic grade.
MATERIALS AND METHODS: Radical prostatectomy (RP) specimens from 56 patients with clinically localized PC, and benign prostatic hyperplasia (BPH) transurethral resection specimens from 31 patients, were assessed for Nedd4L expression using immunohistochemistry.
RESULTS: Nedd4L (P<0.001) expressions were significantly decreased in PC compared to benign prostate tissue. Furthermore, downregulation of Nedd4L (P<0.05) expression correlated with increasing Gleason score.
CONCLUSIONS: These data suggest that prostate cancer cells in vivo may need Nedd4L expression to regulate TGF-beta1 signaling, and that Nedd4L expression might be involved in prostate cancer development.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19004604     DOI: 10.1016/j.ejso.2008.09.015

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  18 in total

Review 1.  SMURF and NEDD4: sharp shooters monitor the gate keepers and ion traffic controllers of lead astray cell.

Authors:  Ammad Ahmad Farooqi; Makhdoom Saad Waseem; Asma M Riaz; Shahzad Bhatti
Journal:  J Membr Biol       Date:  2011-09-15       Impact factor: 1.843

Review 2.  NEDD4-2 (NEDD4L): the ubiquitin ligase for multiple membrane proteins.

Authors:  Pranay Goel; Jantina A Manning; Sharad Kumar
Journal:  Gene       Date:  2014-11-26       Impact factor: 3.688

3.  Role of altered expression of Nedd4L in the pathogenesis of systemic malignancies.

Authors:  Shailendra Kapoor; Tamotsu Takeuchi; Naoe Goto; Yusuke Kito; Mutsuo Furihata
Journal:  Int J Exp Pathol       Date:  2012-10-22       Impact factor: 1.925

4.  The impacts of the interaction of genetic variation, CYP11β2 and NEDD4L, with sodium intake on pediatric obesity with gender difference: a 3-year panel study.

Authors:  M Lee; D Y Kwon; J Park
Journal:  Int J Obes (Lond)       Date:  2016-12-26       Impact factor: 5.095

Review 5.  Gene dysregulations driven by somatic copy number aberrations-biological and clinical implications in colon tumors: a paper from the 2009 William Beaumont Hospital Symposium on Molecular Pathology.

Authors:  Manny D Bacolod; Francis Barany
Journal:  J Mol Diagn       Date:  2010-08-13       Impact factor: 5.568

6.  Decreased expression of Nedd4L correlates with poor prognosis in gastric cancer patient.

Authors:  Chengcheng Gao; Liqun Pang; Chengcheng Ren; Tianheng Ma
Journal:  Med Oncol       Date:  2011-09-11       Impact factor: 3.064

7.  Interaction between DMRT1 function and genetic background modulates signaling and pluripotency to control tumor susceptibility in the fetal germ line.

Authors:  Anthony D Krentz; Mark W Murphy; Teng Zhang; Aaron L Sarver; Sanjay Jain; Michael D Griswold; Vivian J Bardwell; David Zarkower
Journal:  Dev Biol       Date:  2013-03-06       Impact factor: 3.582

8.  HECT domain-containing E3 ubiquitin ligase NEDD4L negatively regulates Wnt signaling by targeting dishevelled for proteasomal degradation.

Authors:  Yi Ding; Yan Zhang; Chao Xu; Qing-Hua Tao; Ye-Guang Chen
Journal:  J Biol Chem       Date:  2013-02-09       Impact factor: 5.157

9.  NEDD4L Protein Catalyzes Ubiquitination of PIK3CA Protein and Regulates PI3K-AKT Signaling.

Authors:  Zixi Wang; Tingting Dang; Tingting Liu; She Chen; Lin Li; Song Huang; Min Fang
Journal:  J Biol Chem       Date:  2016-06-23       Impact factor: 5.157

10.  Genetic variation of NEDD4L is associated with essential hypertension in female Kazakh general population: a case-control study.

Authors:  Nanfang Li; Hongmei Wang; Jin Yang; Ling Zhou; Jing Hong; Yanying Guo; Wenli Luo; Jianhang Chang
Journal:  BMC Med Genet       Date:  2009-12-09       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.